Pfizer and Eli Lilly Trade Slightly Lower Before Earnings Releases

Pfizer, Inc. (NYSE:PFE) will unveil its latest earnings on Tuesday, January 31, 2012. The average estimate of analysts is for profit of 47 cents per share, no change from the company’s actual earnings for the same quarter a year ago. During the past three months, the average estimate has moved down from 50 cents. Between one and three months ago, the average estimate moved down. It has been unchanged at 47 cents during the last month. Analysts are projecting profit to rise by 2.2% versus last year to $2.28.

Last quarter, the company beat estimates by 6 cents, coming in at net income of 62 cents a share versus the estimate of profit of 56 cents a share. It marked the fourth straight quarter of beating estimates. Analysts are projecting a decline of 5.5% in revenue from the year-earlier quarter to $16.59 billion.

Competitors to Watch: Johnson & Johnson (NYSE:JNJ), Merck & Co., Inc. (NYSE:MRK), GlaxoSmithKline plc (NYSE:GSK), Bristol Myers Squibb Co. (NYSE:BMY), Eli Lilly & Co. (NYSE:LLY), Abbott Laboratories (NYSE:ABT), Novartis AG (NYSE:NVS), Mylan Inc. (NASDAQ:MYL), Amgen, Inc. (NASDAQ:AMGN), and Sanofi-Aventis SA (NYSE:SNY).

Eli Lilly & Co. (NYSE:LLY) will unveil its latest earnings on Tuesday, January 31, 2012. The average estimate of analysts is for profit of 80 cents per share, a decline of 27.9% from the company’s actual earnings for the same quarter a year ago. The average estimate is the same as three months ago. Between one and three months ago, the average estimate moved down. It has risen from 79 cents during the last month. For the year, analysts are projecting net income of $4.35 per share, a decline of 8.2% from last year.

Last quarter, the company saw profit of $1.13 per share versus a mean estimate of net income of $1.13 per share. This comes after two consecutive quarters of exceeding expectations. On average, analysts predict $5.9 billion in revenue this quarter, a decline of 4.7% from the year ago quarter. Analysts are forecasting total revenue of $24.13 billion for the year, a rise of 4.5% from last year’s revenue of $23.08 billion.

Competitors to Watch: Pfizer Inc. (NYSE:PFE), Bristol Myers Squibb Co. (NYSE:BMY), Merck & Co., Inc. (NYSE:MRK), Johnson & Johnson (NYSE:JNJ), Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN), GlaxoSmithKline plc (NYSE:GSK), Alkermes, Inc. (NASDAQ:ALKS), Novartis AG (NYSE:NVS), and Abbott Laboratories (NYSE:ABT).